Physician profile
Reuben Walia
NPI 1770877094
$4,869.60
in general payments reported to CMS, 2019-2025
11 companies · $1,773 in 2025
The $1,773 reported for 2025 was more than what 81% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $284 · 2021: $1,099 · 2022: $140 · 2024: $916 · 2025: $1,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,507 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,507.42 |
| Education | $180.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,714.92 | 2019-2025 | |
| Inspire Medical Systems, INC. | $1,542.10 | 2019-2025 | Inspire |
| Axsome Therapeutics, INC. | $450.51 | 2024-2025 | Sunosi |
| Fisher & Paykel Healthcare INC | $368.17 | 2019-2025 | Fisher & Paykel Healthcare |
| Harmony Biosciences LLC | $329.64 | 2020-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $153.70 | 2024-2025 | Lumryz |
| Idorsia Pharmaceuticals US INC | $107.56 | 2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $105.20 | 2025 | |
| Vanda Pharmaceuticals INC. | $44.21 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $29.19 | 2019 | |
| Noctrix Health, INC. | $24.40 | 2025 | Nidra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reuben Walia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.